KURA NASDAQ
Kura Oncology, Inc.
1W: -0.8%
1M: -6.7%
3M: +10.9%
YTD: -4.3%
1Y: +2.1%
3Y: +19.7%
5Y: -44.2%
$9.90
+0.28 (+2.91%)
Pre-Market: $9.97 (+0.07, +0.76%)
Weekly Expected Move ±6.2%
$8
$9
$10
$10
$11
Credit Risk of going bust: lower than 74% of companies Debt: 2.7% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.02 (down 99.8%), Kura Oncology, Inc. would be worth roughly what it owes.
Total debt $24.5M against a stock market value of $880.7M.
Distance to default 8.23 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $7.0M (short-term plus half of long-term), stock volatility 57.8%; Altman Z'' -5.66. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.02 (down 99.8%), Kura Oncology, Inc. would be worth roughly what it owes.
Total debt $24.5M against a stock market value of $880.7M.
Distance to default 8.23 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $7.0M (short-term plus half of long-term), stock volatility 57.8%; Altman Z'' -5.66. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
-0.90
Bearish
0 bullish
0 neutral
1 bearish
Articles (24h)
1
Hourly Sentiment (24h)
-0.90
Bearish
0 bullish
0 neutral
1 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (89)
Will Kura Oncology (KURA) Report Negative Q3 Earnings? What You Should Know
Kura Oncology, Inc. (NASDAQ:KURA) Stock Has Average Price Target of $25.69
Kura Oncology (NASDAQ:KURA) Insider Mollie Leoni Sells 28,802 Shares of Stock
Kura Oncology (NASDAQ:KURA) Insider Mollie Leoni Sells 12,448 Shares of Stock
Kura Oncology (NASDAQ:KURA) Insider Brian Powl Sells 17,020 Shares of Stock
Kura Oncology (NASDAQ:KURA) Insider Brian Powl Sells 15,430 Shares of Stock
Squarepoint Ops LLC Sells 78,432 Shares of Kura Oncology, Inc. $KURA
Corient Private Wealth LP Acquires 70,388 Shares of Kura Oncology, Inc. $KURA
Kura Oncology Launches Caspian Therapeutics with $50 Million Financing to Advance Menin Inhibition as a Potential Disease-Modifying Approach for Diabetes
Kura Oncology appoints Jennifer Fulk as CFO
Legal & General Group Plc Purchases Shares of 61,444 Kura Oncology, Inc. $KURA
Bank of New York Mellon Corp Makes New $2.83 Million Investment in Kura Oncology, Inc. $KURA
KURA Stock Gains 37.6% in a Month: Here's What You Need to Know
Kura Oncology (KURA) Upgraded to Buy: What Does It Mean for the Stock?
Oncology Stocks to Add to Your Portfolio as Cancer Care Evolves
Company News for Aug 26, 2026
Kura Oncology CEO Buys 100,000 Shares for $1.2 Million. Does This Large Buy Bode Well for Shares in 2026?
At a glance: stocks gapping up premarket
Kura Oncology (KURA) Q2 2026 Earnings Call Transcript
Kura Oncology (KURA) is a Great Momentum Stock: Should You Buy?
Does Kura Oncology (KURA) Have the Potential to Rally 178.55% as Wall Street Analysts Expect?
At a glance: stocks gapping up premarket
Q3 EPS Estimates for Kura Oncology Boosted by HC Wainwright
Kura Oncology Q3 EPS Increased by Brookline Capital Markets
Assenagon Asset Management S.A. Trims Holdings in Kura Oncology, Inc. $KURA
Kura Oncology, Inc. Q2 2026 Earnings Call Summary
Kura Oncology (KURA) Reports Q2 Loss, Beats Revenue Estimates
Here are the major earnings after the close Wednesday
C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Tops Revenue Estimates
TELA Bio, Inc. (TELA) Reports Q2 Loss, Lags Revenue Estimates
Kura Oncology Announces Publication in Blood Highlighting Ziftomenib’s Differentiated Binding Profile and Preclinical Activity
Agenus (AGEN) Reports Q2 Loss, Tops Revenue Estimates
Cognition Therapeutics, Inc. (CGTX) Reports Q2 Loss, Lags Revenue Estimates
Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML
Kura Oncology Highlights Darlifarnib’s Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines Development Strategy
Kura Oncology and Kyowa Kirin Announce Publication in Blood of Ziftomenib plus Venetoclax / Azacitidine Combination in Patients with R/R NPM1-m AML
Kura Oncology Reports Strong Clinical Activity and Safety with Darlifarnib + Adagrasib in KRAS G12C-Mutated Solid Tumors
Kura Oncology, Inc. Q1 2026 Earnings Call Summary
QuickLogic Posts Downbeat Q1 Results, Joins Resideo Technologies And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Kura targets 2028 first top line KOMET-017 Phase III results as KOMZIFTI posts $5.8M in first full launch quarter
Kura Oncology (KURA) Reports Q1 Loss, Tops Revenue Estimates
Here are the major earnings after the close Tuesday
Earnings Scheduled For May 12, 2026
Celldex Therapeutics (CLDX) Reports Q1 Loss, Misses Revenue Estimates
Kura Oncology to Participate in Bank of America Securities Healthcare Conference
Will MeiraGTx Holdings PLC (MGTX) Report Negative Q1 Earnings? What You Should Know
Kura Oncology to Report First Quarter 2026 Financial Results
Kura Oncology (KURA) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
KURA Stock Rallies 8% on Strong Preliminary Renal Cancer Study Data
Kura Oncology (KURA) Moves 8.3% Higher: Will This Strength Last?
Kura Oncology (NASDAQ:KURA) Trading Up 9.7% – Here’s What Happened
Kura Oncology, Inc. (NASDAQ:KURA) Given Average Recommendation of “Moderate Buy” by Brokerages
Kura Oncology Advances Kidney Cancer Program With Solid Early-Stage Results
12 Health Care Stocks Moving In Friday's Pre-Market Session
Kura rises after early-stage trial data for kidney cancer therapy
Kura Oncology Reports Darlifarnib Plus Cabozantinib Demonstrates Robust Activity in Patients With Clear Cell Renal Cell Carcinoma Previously Treated With Cabozantinib
Kura Oncology to Present Darlifarnib Plus Cabozantinib Data in Patients with Clear Cell Renal Cell Carcinoma Previously Treated with Cabozantinib at IKCS Europe 2026
Kura Oncology, Inc. $KURA Shares Bought by SG Americas Securities LLC
Assenagon Asset Management S.A. Sells 120,014 Shares of Kura Oncology, Inc. $KURA
Kura Oncology, Inc. (NASDAQ:KURA) Receives Average Rating of “Moderate Buy” from Brokerages
Algert Global LLC Sells 58,194 Shares of Kura Oncology, Inc. $KURA
Implied Volatility Surging for Kura Oncology Stock Options
FY2027 EPS Forecast for Kura Oncology Lowered by Analyst
Kura Oncology (NASDAQ:KURA) Shares Gap Down After Earnings Miss
Kura Oncology anticipates $7B AML opportunity as KOMZIFTI launches and combination strategies advance
Kura Oncology (KURA) Reports Q4 Loss, Misses Revenue Estimates
Kura Oncology Q4 Earnings Summary & Key Takeaways
Kura Oncology GAAP EPS of -$0.92 misses by $0.18, revenue of $17.34M misses by $18.11M
Kura Oncology Reports Fourth Quarter and Full Year 2025 Financial Results
Kura Oncology Reports Fourth Quarter and Full Year 2025 Financial Results
Earnings Scheduled For March 5, 2026
Here are the major earnings before the open Thursday
A Glimpse of Kura Oncology's Earnings Potential
Kura Oncology Q4 2025 Earnings Preview
Kura Oncology, Inc. (NASDAQ:KURA) Given Average Rating of “Moderate Buy” by Brokerages
Kura Oncology to Report Fourth Quarter and Full Year 2025 Financial Results
Kura Oncology to Participate in Three Upcoming Investor Conferences
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Kura Oncology: Safety Profile Of Komzifti Supports My Upgrade To Strong Buy
New Strong Sell Stocks for January 21st
Kura Oncology Highlights Recent Accomplishments, Preliminary KOMZIFTI Revenue and Anticipated 2026 Milestones
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Kura Oncology, Inc. (NASDAQ:KURA) Given Consensus Rating of “Moderate Buy” by Brokerages
Kura Oncology, Inc. (KURA) Discusses Ziftomenib Combination Data in Newly Diagnosed and Relapsed/Refractory NPM1-m and KMT2A-r AML Transcript
Kura Oncology: A Cautious Buy
Kura Oncology: Expect Volatility Following Ziftomenib Phase 1b Data
KOMZIFTI™ (ziftomenib) Added to National Comprehensive Cancer Network® (NCCN) Guidelines for Acute Myeloid Leukemia (AML)
AXQ Capital LP Raises Stock Position in Kura Oncology, Inc. $KURA
Kura Oncology, Inc. (KURA) Discusses FDA Approval of KOMZIFTI for Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia Transcript